D-serine AudRem: R33 Phase

Schizophrenia Clinical Trial

Official title:

D-serine Augmentation of Neuroplasticity-based Auditory Learning in Schizophrenia: R33 Phase

Clinical Trial Details — Status: Suspended

Administrative data

• NCT number: NCT05046353
• Other study ID #: 7725R
• Status: Suspended
• Phase: Phase 1/Phase 2
• Start date: December 1, 2022
• Est. completion date: August 31, 2025

Study information

• Verified date: January 2024
• Source: New York State Psychiatric Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Schizophrenia is a major public health problem associated with cognitive deficits, such as short and long term memory, executive functioning, attention and speed of processing that are amongst the strongest predictors of impaired functional outcome. In addition, schizophrenia patients show reduced "plasticity", defined as reduced learning.

D-serine is a naturally occurring activator of the N-methyl-d-aspartate-type glutamate receptors (NMDAR) in the brain, and this project will assess the D-serine treatment over 16 weeks of a program designed to measure auditory plasticity.

Description:

D-Serine is a naturally occurring substance in the brain that activates the N-methyl-d-aspartate-type glutamate receptor (NMDAR). This receptor is thought to be important in both schizophrenia and plasticity (learning). My model proposes that problems with NMDAR within the brain leads to impaired plasticity, which in turn leads to impaired cognition. d-serine is an ideal NMDAR activator to study because it balances efficacy, availability and safety. Most d-serine studies have used a low dose, but the evidence for efficacy is even stronger for high dose d-serine, as will be tested in the current study. There has only been limited summary of higher dose d-serine, which is another important reason for this study.

In addition to testing a potentially viable treatment in schizophrenia, a positive result would provide opportunities for use of D-serine in other populations (e.g. anxiety disorders or dementia) and stimulate the pharmaceutical industry to utilize this methodology to assess the efficacy of novel NMDAR modulators, using d-serine as a "gold-standard."

The ultimate goal of this two part grant (R61-R33) study is to improve cognitive remediation by augmenting with D-serine.

We recently completed the R61-phase, meeting our predetermined "milestones. " As predicted, D-serine led to significant enhancement of auditory plasticity and electrophysiological measures.

During the three-year R33-phase, we will conduct a study of D-serine of 60 schizophrenia patients, assessing the effects of D-serine over 16 sessions of this program. Most successful, cognitive remediation programs are limited by lengthy (30-50 hours) treatments. Hypothesizing that adding D-serine will increase efficiency of cognitive remediation, successful completion of the R33-phase is defined as significant improvement in global cognition after 16 hours of treatment, and will serve as a pilot study to determine whether future, definitive clinical trials are warranted.

Recruitment information / eligibility

• Status: Suspended
• Enrollment: 60
• Est. completion date: August 31, 2025
• Est. primary completion date: April 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

1. Age between 18 and 50

2. DSM-V diagnosis of schizophrenia or schizoaffective disorder

3. Willing to provide informed consent

4. Auditory Cognitive impairment demonstrated by:

a .MCCB composite domain score less than or equal to 0.5 standard deviation below normal (T score less than or equal to 45) b. And at least one of the following:

5. MCCB verbal memory domain score less than or equal to 0.5 standard deviation below normal (T score less than or equal to 45)

6. Tone matching score of less than or equal to 77.7%

7. Clinically stable for 2 months (CGI less than or equal to 4)

8. Moderate or lower cognitive disorganization (PANSS P2 less than or equal to 4)

9. Medically stable for study participation

10. Willing to use qualified methods of contraception for the study duration and up to 2 months after its end

11. Fluent English speaker

12. Normal hearing

13. Visual acuity corrected to 20/30

14. An estimated Glomerular Filtration Rate (GFR) greater than or equal to 60

15. Taking an antipsychotic medication other than clozapine at a stable dose for at least 4 weeks

16. Judged clinically not to be at significant suicide or violence risk

Exclusion Criteria:

1. Substance abuse (excluding nicotine) within last 60 days

2. ECG abnormality that is clinically significant in the context of study participation in the opinion of the study cardiologist

3. Current clozapine use. Clozapine is excluded for two reasons: to avoid the potential confound of treatment resistant patients and because of clozapine's intrinsic NMDA agonist

4. Participation in study of investigational medication/device within 4 weeks

5. Pregnant women or women of child-bearing potential, who are either not surgically-sterile or for outpatients, using appropriate methods of birth control. Women of child-bearing potential must have a negative serum beta-hCG pregnancy test at screening.

6. Presence of positive history of unstable significant medical or neurological illness

7. Positive toxicology screen for any substances of abuse

8. Subjects with suicidal ideation with intent or plan (indicated by affirmative answers to items 4 or 5 of the Suicidal Ideation section of the baseline C-SSRS) in the 6 months prior to screening or subjects who represent a significant risk of suicide in the opinion of the investigator

Related Conditions & MeSH terms

• Mood Disorders
• Psychotic Disorders
• Schizo Affective Disorder
• Schizophrenia

Intervention

Drug:
• D-serine
Auditory remediation +/-D-serine

Other:
• Placebo
Auditory remediation +/-D-serine

Locations

Country	Name	City	State
United States	NYSPI	New York	New York

Sponsors (3)

Lead Sponsor	Collaborator
New York State Psychiatric Institute	Nathan Kline Institute for Psychiatric Research, National Institute of Mental Health (NIMH)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Auditory Cognition	MATRICS cognitive battery verbal domain	16 weeks